Contributor Disclosures for Fever in the Toddler
Role Name Disclosure Details
Author Maria Y Kwok, MD, MPH, Assistant Professor of Pediatrics, Department of Emergency Medicine, Columbia University College of Physicians and Surgeons; Consulting Staff, Morgan Stanley Children's Hospital of New York-Presbyterian Nothing to discloseDetails
Coauthor Hector Vazquez, MD, Fellow, Department of Pediatrics, Section of Emergency Medicine, Morgan Stanley Children's Hospital of New York-Presbyterian Nothing to discloseDetails
Coauthor Daniel Isaacman, MD, Chief, Department of Pediatric Emergency Medicine, Children's Hospital of King's Daughter Nothing to discloseDetails
Medical Editor Rosemary Johann-Liang, MD, Medical Officer, Infectious Diseases and Pediatrics, Division of Special Pathogens and Immunological Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration Nothing to discloseDetails
Pharmacy Editor Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc
Avanir Pharma
Details
Managing Editor Mark R Schleiss, MD, American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota School of Medicine Nothing to discloseDetails
CME Editor Robert W Tolan Jr, MD, Chief of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine GlaxoSmithKline
MedImmune
MedImmune
Merck
Novartis
sanofi pasteur
sanofi pasteur
sanofi pasteur
Tap
Details
Chief Editor Russell W Steele, MD, Professor and Vice Chairman, Department of Pediatrics, Head, Division of Infectious Diseases, Louisiana State University Health Sciences Center NoneDetails









Contributor:
Contributor Disclosure:
Maria Y Kwok, Author  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Hector Vazquez, Coauthor  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Daniel Isaacman, Coauthor  The contributor discloses no conflict of interest. 









Contributor Disclosure


Contributor:
Contributor Disclosure:
Rosemary Johann-Liang, Medical Editor  The contributor discloses no conflict of interest. 






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Mary L Windle

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Pfizer Inc
StockInvestment from broker recommendation 
Avanir Pharma
StockInvestment from broker recommendation 
Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Mark R Schleiss

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

Off label or investigational use of medication






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Robert W Tolan, Jr

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

GlaxoSmithKline
HonorariaSpeaking and teaching 
MedImmune
HonorariaConsulting 
MedImmune
HonorariaSpeaking and teaching 
Merck
HonorariaSpeaking and teaching 
Novartis
HonorariaSpeaking and teaching 
sanofi pasteur
Grant/research fundsUnrestricted research grant 
sanofi pasteur
HonorariaConsulting 
sanofi pasteur
HonorariaSpeaking and teaching 
Tap
HonorariaSpeaking and teaching 
Off label or investigational use of medication
Several medications used in routine pediatric practice are used in an off-label fashion. We participate in a research studies of off-label uses of medications through the NIAID Antiviral Collaborative Study Group.






 

CONTRIBUTOR DISCLOSURE FORM


Contributor Name:
Russell W Steele

 DECLARATION STATEMENT
I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity.
COMMERCIAL INTEREST
(Name of Organization)
Self
Spouse/
Partner
NATURE OF RELEVANT FINANCIAL RELATIONSHIP
What was received?*
For what role?**

None
NoneNone 
Off label or investigational use of medication
none